Dianthus SVP sells 30,000 shares after option exercise
Dianthus Therapeutics SVP and General Counsel Adam M. Veness reported an exercise-and-sale transaction in company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Dianthus Therapeutics SVP and General Counsel Adam M. Veness reported an exercise-and-sale transaction in company stock. He exercised stock options to acquire 30,000 shares of common stock at a strike price of $17.88 per share, then sold 30,000 shares in open-market trades at weighted average prices of $80.34 and $81.38 per share. These sales were executed under a Rule 10b5-1 trading plan. Following the transactions, he held no shares of common stock directly but retained 80,000 stock options that continue to vest over four years beginning January 1, 2024.
Insider Trade Summary 10b5-1
Exercise and Sale: 30,000 shares ($1.89M approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Veness Adam M
Role
SVP, General Counsel and Sec.
Sold
30,000 shs ($2.42M)
Approx. gross sale proceeds
$2.42M
Approx. exercise cost
$536K
Approx. pre-tax spread
$1.89M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 30,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 30,000 | $17.88 | $536K |
| Sale | Common Stock | 16,771 | $80.34 | $1.35M |
| Sale | Common Stock | 13,229 | $81.38 | $1.08M |
Holdings After Transaction:
Stock Option (Right to Buy) — 80,000 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 18, 2026.
- F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $80.00 to $80.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $81.00 to $81.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4. The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
Key Figures
Shares sold: 30,000 shares
Weighted average sale price 1: $80.34 per share
Weighted average sale price 2: $81.38 per share
+4 more
7 metrics
Shares sold
30,000 shares
Open-market sales of common stock on 2026-06-17
Weighted average sale price 1
$80.34 per share
Common stock sale transaction on 2026-06-17
Weighted average sale price 2
$81.38 per share
Common stock sale transaction on 2026-06-17
Options exercised
30,000 shares
Stock option exercise into common stock on 2026-06-17
Option strike price
$17.88 per share
Stock Option (Right to Buy) conversion price
Options remaining
80,000 options
Stock options held after transactions
Common shares held after
0 shares
Direct common stock ownership after sales
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), vesting
4 terms
Rule 10b5-1 trading plan regulatory
"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above is a weighted average price. The shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with a conversion or exercise price of 17.8800"
vesting financial
"shares of common stock underlying this stock option award vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did DNTH executive Adam M. Veness report?
Adam M. Veness reported exercising 30,000 stock options and selling 30,000 shares of Dianthus Therapeutics common stock. The trades were open-market sales executed under a Rule 10b5-1 trading plan at weighted average prices around $80–$81 per share.
At what price did the DNTH executive exercise stock options?
Adam M. Veness exercised stock options to acquire 30,000 Dianthus Therapeutics shares at a strike price of $17.88 per share. These options are part of a larger award that vests in equal monthly installments over four years starting January 1, 2024.
Does the DNTH insider still hold common stock after these transactions?
After the reported transactions, Adam M. Veness held zero shares of Dianthus Therapeutics common stock directly. However, he continued to hold 80,000 stock options, reflecting an ongoing equity-based compensation position with the company.
Were the DNTH insider sales made under a Rule 10b5-1 plan?
Yes, the filing states the reported sales were effected under a Rule 10b5-1 trading plan adopted by Adam M. Veness. Such plans pre-schedule trades, indicating the timing of these open-market sales was established in advance rather than decided opportunistically.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates